Investors do not invest in companies they have never heard of so getting out and talking to investors, both in person and via all media platforms including social media, is a major part of my job as CEO.
We have more positive clinical trial data than any biotech listed on the ASX. The problem with bisantrene has never been that it didn't work, but that it was impractical to use for most cancer patients. This is what we have solved with RC220, and along with the preclinical work we have done, we have identified the most valuable cancer indications to target. We may not succeed (after all RAC is a speculative biotech), but from my perspective the risk/reward ratio looks very attractive. Big market, proven clinical efficacy, and long IP life is what any smart biotech investor wants to see.
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-45
- There are more pages in this discussion • 190 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.075(4.02%) |
Mkt cap ! $304.8M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.86 | $1.76 | $348.2K | 192.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5612 | $1.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 3567 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.78 |
Change
-0.075 ( 5.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.81 | $1.86 | $1.76 | 27553 | ||
| Last updated 15.55pm 14/06/2024 ? | |||||
| RAC (ASX) Chart |